Prof. Dr. Burkhard Tümmler participates in RESIST research project C3.
| My Research Interest in RESIST |
Our research focus in RESIST is the analysis of the lower airway microbial metagenome of individuals with chronic lung disease. Understanding the abundance and diversity of non-pathogenic and (opportunistic) pathogenic species in the healthy population and the succession of characteristic subpopulations over time in patients provides key information to pursue the goal of ‘curing a patient’ by reverting a harmful to a healthy microbiome.
We hypothesize that protective factors produced by representatives of the commensal microflora can antagonize the spread of pervasive pathogens. In- depth genome analysis of the identified ‘key players’ in the airway microflora will therefore be used to identify potentially protective factors/substances. If successful, this may pave the way for new forms of therapy that could use naturally produced but so far unknown or underexplored secondary metabolites as starting points for drug candidates.
Prof. Tümmler about his scientific work
Prof. Dr. Burkhard Tümmler – Curriculum Vitae
Current Position
Since 1993 Full (C3) Professor, Clinical Research ‘Molecular pathology of cystic fibrosis’, Clinic for Pediatric Pneumology, Allergology and Neonatology, MHH
Undergraduate and Postgraduate Training
1971 – 1976 Biochemistry, Technical University of Hannover
1974 – 1981 Medicine, Hannover Medical School
1979 Dr. rer. nat. (Physical Chemistry, summa cum laude)
1984 Dr. med. (Human Genetics, summa cum laude)
1991 Habilitation for Biochemistry, MHH
Academic and Research Posts
1976 – 1979 Scientific Assistant, Institute for Biophysical Chemistry, MHH
1981 – 1983 Postdoc, Hospital for Sick Children, Toronto
1983 – 1993 Research Associate, Institute for Biophysical Chemistry, MHH
Since 1983 Consultant of the Cystic Fibrosis Clinic, Children’s Clinic, MHH
Since 1993 Head, Clinical Research Group ‘Molecular pathology of cystic fibrosis’
Other Scientific Roles
Since 1992 Member of the Editorial Boards of Electrophoresis (1992-2002), Biochimica Biophysica Acta Molecular Basis of Disease (1994-2000), environmental microbiology (since 1999), Journal of Cystic Fibrosis (2004-2011), Journal of Bacteriology (2005- 2014), Microbes and Infection (since 2015); International Journal of Medical Microbiology (since 2017)
2000 – 2010 Speaker, DFG IRTG ‘Pseudomonas: Pathogenicity and Biotechnology’
2002 – 2004 Editor, Genome Letters
2006 – 2012 Substitute Chair ,Forschungsgemeinschaft Mukoviszidose’
Since 2011 Coordinator, Disease Area ‘Cystic Fibrosis’, German Center for Lung Research (DZL)
Since 2014 Member of the ‘Faculty of 1000’
Awards and Prizes
1971 – 1976 German National Scholarship Foundation (Studienstiftung des Deutschen Volkes)
1992 Windorfer Prize for Cystic Fibrosis Research
1993 Schülke Prize for Hygiene
1994 Rudolf-Schoen-Prize for Clinical Research
10 Selected Publications (of > 321 original publications)
|
Guan S, Munder A, Hedtfeld S, Braubach P, Glage S, Zhang L, Lienenklaus S, Schultze A, Hasenpusch G, Garrels W, Stanke F, Miskey C, Johler SM, Kumar Y, Tümmler B, Rudolph C, Ivics Z, Rosenecker J. Self- assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019; 14: 287-297. Pienkowska K, Wiehlmann L, Tümmler B. Metagenome – inferred bacterial replication rates in cystic fibrosis airways. J Cyst Fibros. 2019 Jan 23. pii: S1569-1993(19)30010-4. doi: 10.1016/j.jcf.2019.01.003. Graeber SY, Dopfer C, Naehrlich L, Gyulumyan L, Scheuermann H, Hirtz S, Wege S, Mairbäurl H, Dorda M, Hyde R, Bagheri-Hanson A, Rueckes-Nilges C, Fischer S, Mall MA, Tümmler B. Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis. Am J Respir Crit Care Med. 2018; 197: 1433-1442. Moran Losada P, Chouvarine P, Dorda M, Hedtfeld S, Mielke S, Schulz A, Wiehlmann L, Tümmler B. The cystic fibrosis lower airways microbial metagenome. ERJ Open Res. 2016;2(2). pii: 00096-2015. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, Morales G, Köhler T, van Delden C, Weinel C, Slickers P, Tümmler B. Population structure of Pseudomonas aeruginosa. Proc Natl Acad Sci U S A. 2007; 104:8101-6. Nelson KE, Weinel C, Paulsen IT, Dodson RJ, Hilbert H, Martins dos Santos VA, Fouts DE, Gill SR, Pop M, Holmes M, Brinkac L, Beanan M, DeBoy RT, Daugherty S, Kolonay J, Madupu R, Nelson W, White O, Peterson J, Khouri H, Hance I, Chris Lee P, Holtzapple E, Scanlan D, Tran K, Moazzez A, Utterback T, Rizzo M, Lee K, Kosack D, Moestl D, Wedler H, Lauber J, Stjepandic D, Hoheisel J, Straetz M, Heim S, Kiewitz C, Eisen JA, Timmis KN, Düsterhöft A, Tümmler B, Fraser CM. Complete genome sequence and comparative analysis of the metabolically versatile Pseudomonas putida KT2440. Environ Microbiol. 2002; 4: 799-808. Bronsveld I, Mekus F, Bijman J, Ballmann M, de Jonge HR, Laabs U, Halley DJ, Ellemunter H, Mastella G, Thomas S, Veeze HJ, Tümmler B. Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings. J Clin Invest. 2001; 108:1705-15. Kälin N, Claass A, Sommer M, Puchelle E, Tümmler B. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest. 1999; 103:1379-89. Kubesch P, Dörk T, Wulbrand U, Kälin N, Neumann T, Wulf B, Geerlings H, Weissbrodt H, von der Hardt H, Tümmler B. Genetic determinants of airways‘ colonisation with Pseudomonas aeruginosa in cystic fibrosis. Lancet. 1993; 341: 189-93. Römling U, Grothues D, Bautsch W, Tümmler B. A physical genome map of Pseudomonas aeruginosa PAO. EMBO J. 1989; 8: 4081-9. |
|
